This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, W.
Right arrow Articles by Qiao, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, W.
Right arrow Articles by Qiao, L.

 Previous Article  |  Next Article 

Journal of Virology, September 1999, p. 7877-7881, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Human Papillomavirus Type 16 E7 DNA Vaccine: Mutation in the Open Reading Frame of E7 Enhances Specific Cytotoxic T-Lymphocyte Induction and Antitumor Activity

Wei Shi,1 Ping Bu,1 Jianzhong Liu,1 Axel Polack,2 Susan Fisher,3 and Liang Qiao1,*

Department of Microbiology and Immunology1 and Cardinal Bernardin Cancer Center,3 Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, and National Research Center for Environment and Health, Institute of Clinical Molecular Biology and Tumor Genetics, D-81377 Munich, Germany2

Received 11 January 1999/Accepted 25 May 1999

A human papillomavirus type 16 E7 DNA vaccine with the open reading frame encoding mutations in two zinc-binding motifs expressed a rapidly degraded E7 protein. This vaccine induced a significantly stronger E7-specific cytotoxic T-lymphocyte response and better tumor protection in mice than did a wild-type E7 DNA vaccine expressing a stable E7 protein.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Stritch School of Medicine, Building 105, Room 2890, Loyola University Medical Center, 2160 South First Ave., Maywood, IL 60153. Phone: (708) 327-3481. Fax: (708) 216-1196. E-mail: lqiao{at}luc.edu.

Journal of Virology, September 1999, p. 7877-7881, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Huang, Y., Obholzer, N., Fayad, R., Qiao, L. (2005). Turning On/Off Tumor-Specific CTL Response during Progressive Tumor Growth. J. Immunol. 175: 3110-3116 [Abstract] [Full Text]  
  • Huang, Y., Fayad, R., Smock, A., Ullrich, A. M., Qiao, L. (2005). Induction of Mucosal and Systemic Immune Responses against Human Carcinoembryonic Antigen by an Oral Vaccine. Cancer Res. 65: 6990-6999 [Abstract] [Full Text]  
  • Wiethe, C., Dittmar, K., Doan, T., Lindenmaier, W., Tindle, R. (2003). Enhanced Effector and Memory CTL Responses Generated by Incorporation of Receptor Activator of NF-{kappa}B (RANK)/RANK Ligand Costimulatory Molecules into Dendritic Cell Immunogens Expressing a Human Tumor-Specific Antigen. J. Immunol. 171: 4121-4130 [Abstract] [Full Text]  
  • Schreurs, M. W. J., Scholten, K. B. J., Kueter, E. W. M., Ruizendaal, J. J., Meijer, C. J. L. M., Hooijberg, E. (2003). In Vitro Generation and Life Span Extension of Human Papillomavirus Type 16-Specific, Healthy Donor-Derived CTL Clones. J. Immunol. 171: 2912-2921 [Abstract] [Full Text]  
  • Devaraj, K., Gillison, M. L., Wu, T.-C. (2003). DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. CROBM 14: 345-362 [Abstract] [Full Text]  
  • Wiethe, C., Dittmar, K., Doan, T., Lindenmaier, W., Tindle, R. (2003). Provision of 4-1BB Ligand Enhances Effector and Memory CTL Responses Generated by Immunization with Dendritic Cells Expressing a Human Tumor-Associated Antigen. J. Immunol. 170: 2912-2922 [Abstract] [Full Text]  
  • Eiben, G. L., Velders, M. P., Schreiber, H., Cassetti, M. C., Pullen, J. K., Smith, L. R., Kast, W. M. (2002). Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice. Cancer Res. 62: 5792-5799 [Abstract] [Full Text]  
  • Steller, M. A. (2002). Cervical Cancer Vaccines: Progress and Prospects. Reproductive Sciences 9: 254-264 [Abstract]  
  • Shi, W., Liu, J., Huang, Y., Qiao, L. (2001). Papillomavirus Pseudovirus: a Novel Vaccine To Induce Mucosal and Systemic Cytotoxic T-Lymphocyte Responses. J. Virol. 75: 10139-10148 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»